Page last updated: 2024-09-03

imatinib mesylate and Blast Crisis

imatinib mesylate has been researched along with Blast Crisis in 282 studies

Research

Studies (282)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	177 (62.77)	29.6817
2010's	95 (33.69)	24.3611
2020's	10 (3.55)	2.80

Authors

Authors	Studies
Aoki, M; Ishikawa, M; Kanda, Y; Maki, A; Matsumura, I; Nakamae, H; Ohmine, K; Ono, T; Sakaida, E; Shibayama, H; Yamamoto, M	1
Baerlocher, GM; Egeli, DB; Hanfstein, B; Lauseker, M; Müller, MC; Pfirrmann, M; Saussele, S	1
Beck, JC; Patel, SA	1
Copland, M	1
Bauduer, F; Bris, YL; Cayuela, JM; Chabane, K; Chevallier, P; Cony-Makhoul, P; Dulucq, S; Flandrin-Gresta, P; Hayette, S; Jeune, CL; Legros, L; Mahon, FX; Maisonneuve, H; Nicolini, FE; Rea, D; Roy, L; Sloma, I	1
Bari, S; Chan, ZE; Cheung, AMS; Chng, WJ; Chuah, C; Hwang, WYK; Krishnan, V; Lee, KL; Lim, MGL; Makheja, M; Nawaz, Z; Ong, ST; Ouyang, J; Prabhakar, S; Rackham, O; Rayan, NA; Ren, X; Schmidt, F; Tan, TZ; Than, H; Venkatesh, PN; Yu, M	1
Branford, S; Dang, P; Hughes, TP; Kok, CH; Saunders, VA; Shanmuganathan, N; White, D; Yeung, D	1
Abdullah, SM; Guru, SA; Mirza, MAB; Rizvi, A; Saxena, A	1
Chen, C; Fu, Y; Huang, T; Wang, S; Wang, X; Xu, M; Yin, X; Zhou, M	1
Biondi, A; Culic, S; De Bont, E; de Moerloose, B; Guilhot, J; Kalwak, K; Lausen, B; Li, CK; Meyran, D; Millot, F; Petit, A; Sedlacek, P; Suttorp, M	1
Arous, R; Benchabane, H; Boudiaf, H; Boukhelal, H; Chikhi, L; Ezziane, K; Hakem, S; Himrane, M; Rouis, NO	1
Ahmadi, A; Anower-E-Khuda, F; Bajaj, J; Blevins, A; Esko, JD; Ginsberg, MH; Hamilton, M; Ito, T; Karlseder, J; Koechlein, CS; Kritzik, M; Kwon, HY; Lytle, N; Park, PW; Reya, T; Spinler, K; Sun, H; Weeks, J; Zimdahl, B	1
Hunger, SP	1
Baurmann, H; Casper, J; Cross, NCP; Dang, TA; Dietze, L; Döhner, K; Fabarius, A; Haferlach, C; Haferlach, T; Hänel, A; Hochhaus, A; Hofmann, WK; Jawhar, M; Lathan, B; Link, H; Lotfi, S; Maywald, O; Metzgeroth, G; Mielke, S; Müller, L; Naumann, N; Panse, J; Platzbecker, U; Prümmer, O; Reiter, A; Schwaab, J; Thomssen, H; Töpelt, K; Vieler, T	1
Asemissen, AM; Dierlamm, J	1
Horiuchi, T; Kato, S; Kawamura, T; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Nagao, S; Okada, Y; Saga, R; Sato, K; Tachi, N; Takano, K; Teramoto, M; Watanabe, J; Yamamura, T	1
Hirano, M; Imai, Y; Imoto, S; Jimbo, K; Kawamata, T; Miyano, S; Ochi, K; Ogawa, M; Ohno, N; Shimizu, E; Takahashi, N; Tojo, A; Uchimaru, K; Yamaguchi, R; Yokoyama, K; Yokoyama, N	1
Eskazan, AE	1
Bennaceur-Griscelli, A; Bonnet, ML; Cayssials, E; Chomel, JC; Desterke, C; Pagliaro, S; Rahban, H; Sorel, N; Turhan, AG; Voldoire, M	1
Alcazer, V; Bidet, A; Cony-Makhoul, P; Dulucq, S; Etienne, G; Fossard, G; Hayette, S; Heiblig, M; Mahon, FX; Morisset, S; Nicolini, FE; Schmitt, A; Sobh, M	1
Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M	1
Junyavoraluk, A; Owattanapanich, W; Rujirachun, P; Sirinvaravong, S; Suvannarerg, V	1
Eigendorff, E; Ernst, T; Hochhaus, A	1
Hu, J; Li, Y; Song, H; Wu, T	1
Blanco, ML; Oñate, G; Pratcorona, M	1
Bombelli, S; Boultwood, J; Branford, S; Citterio, S; Crespiatico, I; D'Aliberti, D; Fontana, D; Gambacorti-Passerini, C; Khandelwal, P; Kim, DW; Magistroni, V; Massimino, L; Mauri, M; Mezzatesta, C; Morotti, A; Nava, M; Parker, W; Perego, R; Piazza, R; Pirola, A; Readelli, S; Rigolio, R; Saglio, G; Schreiber, A; Sharma, N; Viltadi, M; Wang, P; Yeung, D	1
Fukuda, T; Kasama, T; Miura, O; Suwa, S; Uchida, E; Watanabe, K; Yoshimoto, R	1
Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L	1
De Souza, C; Etienne, G; Fan, X; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kalaycio, ME; Kantarjian, HM; Kim, DW; Kurokawa, M; Larson, RA; Rosti, G; Saglio, G; Shou, Y	1
Cross, NC; Fabarius, A; Gosenca, D; Haferlach, C; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Schwaab, J	1
Chen, L; Ericson, SG; Goldberg, SL; Guerin, A; Kaminsky, M; Liu, N; Macalalad, AR; Wu, EQ	1
Leser, U; Leutz, A; Rosenbauer, F; Scheller, M; Schönheit, J; Zimmermann, K	1
Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D	1
Doki, N; Harada, H; Harada, Y; Inoue, D; Izawa, K; Kakihana, K; Katayama, Y; Kawabata, KC; Kitamura, T; Kitaura, J; Maehara, A; Matsui, T; Nakahara, F; Nishimura, K; Ohashi, K; Oki, T; Sada, A; Togami, K; Uchida, T; Yoshioka, K	1
Lin, L; Lu, XJ; Song, XB; Wang, J; Ye, YX; Ying, BW; Zhou, J; Zhou, Y; Zhou, YH	1
Adamaki, M; Athanasiadou, A; Divane, A; Karytianou, A; Moschovi, M; Tourkantoni, N	1
Ai, HS; Dong, Z; Guo, M; Hu, KX; Li, BX; Qiao, JH; Sun, QY; Yao, B; Yu, CL; Zhang, ZC	1
Boissel, N; Borthakur, G; Brummendorf, TH; Capolongo, L; Carpinelli, P; Cortes, JE; Davite, C; Dombret, H; Jabbour, E; Kantarjian, H; Mariani, M; Schafhausen, P	1
Cui, ZG; Li, GL; Shi, X; Wang, YY; Xu, H; Zhao, HG; Zhao, T; Zhou, Y	1
Bardy-Bouxin, N; Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Matczak, E; Shapiro, M; Turkina, AG; Turnbull, K	1
Fabarius, A; Haaß, W; Haferlach, C; Hehlmann, R; Hofmann, WK; Kleiner, H; Müller, MC; Schlegelberger, B; Seifarth, W; Weiß, C	1
Angriman, F; Arbelbide, JA; Gimenez Conca, AD; Gutierrez Acevedo, MN; Michelángelo, H; Otero, V; Rossi, MS	1
Hussain, S; Usman Shaikh, M	1
Chen, J; Chen, S; Jin, Z; Lai, J; Li, Y; Lu, Y; Xu, L; Xu, Y; Yang, L; Yu, W; Zha, X; Zhang, Y	1
Andreeff, M; Carter, BZ; Champlin, RE; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Mak, PY; McQueen, T; Ruvolo, VR; Schober, W	1
Dong, F; Liu, J; Luan, C; Shao, H; Sun, C; Zhang, G; Zhang, X	1
Bolton-Gillespie, E; Cerny-Reiterer, S; Dasgupta, Y; Gornicka, B; Hantschel, O; Hoser, G; Kantekure, K; Koptyra, M; Müschen, M; Nieborowska-Skorska, M; Richardson, C; Roy, D; Skorski, T; Stoklosa, T; Valent, P; van der Kuip, H; Wasik, MA	1
Jiang, H; Jiang, Q; Lai, Y; Qin, Y; Shi, H	1
Carraro, F; Chiarenza, A; Manetti, F; Naldini, A; Petricci, E; Ruat, M; Taddei, M	1
Cella, D; Cortes, J; Reisman, A; Shapiro, M; Whiteley, J	1
Fang, L; Li, J; Tu, H; Wan, Q; Wu, Q; Yang, Y; Zhang, X	1
Maschan, A; Miakova, N; Novichkova, G; Persiantseva, M	1
Liu, HB; Wang, W; Zhang, M	1
Chen, W; Wang, Z	1
Borthakur, G; Cortes, J; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Maiti, A; O'Brien, S; Ravandi, F	1
Lee, S; Song, S; Westfall, DE; Zhang, L	1
Adachi, T; Aikawa, E; Akiyama, M; Kawauchi, K; Motoji, T; Ozaki, K; Yamada, O	1
Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR	1
Dashti, A; Kawamata, N; Koeffler, HP; Lu, D; Miller, B; Moore, S; Ogawa, S; Schreck, R	1
Seth, R; Thavaraj, V	1
Chi, HS; Cho, YU; Chung, HJ; Kim, KH; Lee, JH; Park, CJ; Seo, EJ	1
Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C	1
Alberti, D; Alimena, G; Baccarani, M; Bassi, S; Bocchia, M; Breccia, M; Castagnetti, F; Ferrara, F; Luatti, S; Martinelli, G; Marzocchi, G; Miglino, M; Palandri, F; Pane, F; Pungolino, E; Rege-Cambrin, G; Rosti, G; Saglio, G; Specchia, G; Testoni, N; Varaldo, R; Zuffa, E	1
Deliliers, GL; Ghidoni, R; Onida, F; Radaelli, F; Ricci, C; Saporiti, G; Servida, F; Todoerti, K	1
Gora-Tybor, J; Robak, T	1
Bakhshi, S; Das, P; Gupta, SD; Kalita, D; Radhakrishnan, S; Singh, S	1
Irvine, DA; Shepherd, JD	1
Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S	1
Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J	1
Minami, Y; Stuart, SA; Wang, JY	1
Cortes, J; Kantarjian, H; Mone, M; Silver, RT; Waltzman, R	1
Aftimos, P; Nasr, F	1
Cortes, JE; Jabbour, E; Jones, D; Kantarjian, HM; Reddy, NG; Yao, H; Zhang, L; Zhang, WW	1
Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S	1
Gordon, MY; Patel, H	1
Berendse, HW; Janssen, JJ; Merle, PA; Ossenkoppele, GJ; Schuurhuis, GJ	1
Hu, P; Meng, F; Shen, Z; Wang, J; Wang, Y; Wei, Y; Yin, O; Zhou, L	1
Andreeff, M; Carter, BZ; Chen, W; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Schober, WD	1
Schatz, DG; Strout, MP	1
Casellas, R; Duy, C; Feldhahn, N; Groffen, J; Heisterkamp, N; Henke, N; Hoffmann, TK; Hofmann, WK; Iacobucci, I; Jumaa, H; Kim, YM; Klemm, L; Kuchen, S; Li, Z; Lieber, MR; Martinelli, G; Müschen, M; von Levetzow, G	1
Mitani, K; Sasaki, K	1
Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP	1
Chang, W; Hu, Z; Huang, M; Ou, D; Zhang, Y; Zhou, J	1
Ali, R; Budak, F; Karkucak, M; Korkmaz, S; Nazlioglu, HO; Ozcelik, T; Ozkalemkas, F; Ozkocaman, V; Pekgoz, M; Tunali, A; Yakut, T	1
Ahn, JS; Chung, J; Hyun, MS; Joo, YD; Jung, CW; Kim, BK; Kim, CS; Kim, DY; Kim, HJ; Kim, I; Kim, MK; Kim, SH; Kim, SJ; Koh, Y; Lee, JH; Lee, KH; Park, E; Park, S; Shin, HJ; Sohn, SK; Song, HS; Yoon, SS	1
Bui, TV; Carroll, M; Gruber, JJ; Lum, JJ; Mancuso, A; Melo, JV; Perl, AE; Sanchez, PV; Sayed, N; Swider, CR; Thompson, CB; Tong, X; Tuttle, SW; Zhao, F	1
Al-Seraihy, A; Al-Shehri, A; Belgaumi, AF; Owaidah, TM	1
Kashimura, M; Ohyashiki, K	1
Schiffer, CA; Zonder, JA	2
Ahn, KS; Kim, BK; Kim, KI; Koh, Y; Lee, DS; Oh, JM; Park, J; Won, NH; Yoon, SS	1
Borges, LF; Cahill, DP; Kahle, KT; Nahed, BV; Naunheim, MR; Soupir, CP; Walcott, BP	1
Fang, B; Han, Q; Li, N; Song, Y; Zhao, RC	1
Clark, RE; Dong, M; Etienne, G; Gallagher, N; Haque, A; Hochhaus, A; Hoenekopp, A; Hughes, TP; Issaragrisil, S; Kantarjian, HM; Kim, DW; Larson, RA; le Coutre, P; Lobo, C; Pasquini, R; Saglio, G	1
Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C	1
Kimura, F; Kobayashi, A; Kobayashi, S; Nakamura, Y; Osawa, Y; Sato, K	1
Bradley-Garelik, MB; Cortes, J; Dombret, H; Erben, P; Goh, YT; Hochhaus, A; Maloisel, F; Masszi, T; Paquette, R; Pasquini, R; Saglio, G; Zhu, C	1
Chen, M; Li, J; Luo, SK; Su, C; Xu, DR; Zou, WY	1
Apperley, JF; Clark, RE; Daghistani, M; De Melo, VA; Foroni, L; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Paliompeis, C; Reid, AG; Wang, L	1
Alimena, G; Breccia, M; Capria, S; Foà, R; Iori, AP; Meloni, G	1
Hochhaus, A; Leitner, AA; Müller, MC	1
Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR	1
Han, K; Kim, M; Kim, Y; Lee, SA; Lim, J	1
Iriyama, C; Ishikawa, K; Ishikawa, Y; Kaneda, N; Kiyoi, H; Kobayashi, M; Minami, Y; Mori, Y; Naoe, T; Ozawa, Y; Sakai, K; Suzuki, T	1
Alimena, G; Breccia, M; Cannella, L; De Propris, MS; Diverio, D; Federico, V; Loglisci, G; Nanni, M; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A	1
Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y	1
Akiyama, M; Furukawa, T; Kawauchi, K; Machida, M; Matsuoka, R; Mitsuishi, T; Motoji, T; Ozaki, K; Wang, YH; Yamada, H; Yamada, O	1
Baig, MA; Dutcher, JP; Lee, SH; Paietta, E; Racevskis, J; Wiernik, PH	1
Bergamini, C; Bonifacio, M; Carcereri de Prati, A; Cavalieri, E; Fato, R; Guardalben, E; Pizzolo, G; Rigo, A; Suzuki, H; Vinante, F	1
Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X	1
Akaogi, T; Kawata, E; Kobayashi, Y; Tanaka, T	1
Guo, L; He, L; Li, J; Xu, G; Yu, S	1
Chatziantoniou, V; Kotsopoulou, M; Maltezas, D; Mitsouli-Mentzikof, C; Papanikolaou, X; Triantafillopoulou, ID; Zoi, A	1
Bagadi, S; Das, B; Pany, A; Saikia, T	1
Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS	1
Dorlhiac-Llacer, PE; Gallagher, NJ; Jootar, S; Masszi, T; Nicolini, FE; Powell, BL; Shen, Z; Szczudlo, T; Turkina, A; Zheng, M	1
Andreeff, M; Carter, BZ; Cortes, J; Kantarjian, H; Konopleva, M; Mak, DH; Schober, WD; Wang, RY	1
Chosa, N; Fukudome, T; Hisakata, T; Horikawa, N; Ito, M; Kanda, Y; Kawano, N; Kugimiya, H; Okuda, S; Sakurai, R; Ueda, A; Yamashita, K; Yoshida, S	1
Baccarani, M; Blakesley, RE; Gallagher, NJ; Giles, FJ; Gillis, K; Goldberg, SL; Hochhaus, A; Kantarjian, HM; Larson, RA; le Coutre, PD; Mahon, FX; Ottmann, OG	1
Abou-Mourad, YR; Barnett, MJ; Broady, RC; Forrest, DL; Hogge, DE; Nantel, SH; Narayanan, S; Nevill, TJ; Power, MM; Shepherd, JD; Song, KW; Sutherland, HJ; Tantiworawit, A; Toze, CL	1
Chen, BB; He, HS; Su, GP	1
Gavish, I; Koren-Michowitz, M; Levi, I; Nagler, A; Naparstek, E; Rowe, JM; Shimoni, A; Volchek, Y	1
Ji, JM; Ji, O; Jiang, PJ; Shen, Q; Wu, Y; Yu, H; Zhang, YC; Zhu, GR	1
Fang, BZ; Xie, J; Zhang, X	1
Juan, WC; Ong, ST	1
Bang, JH; Branford, S; Choi, SY; Hughes, TP; Kim, DW; Park, JE; Prime, JA; Ross, DM; Yeung, DT	1
Brunstein, C; Cayci, Z; Rogosheske, J; Shune, L; Ustun, C	1
Hiwase, DK; Hughes, TP	1
Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J	1
Hao, SG; Liang, H; Ma, LY; Tao, R; Yan, JS; Yang, H	1
Fabarius, A; Giehl, M; Haaß, W; Hofmann, WK; Nittka, S; Schrotz-King, P; Seifarth, W; Stehle, M	1
Bernardo, PS; Maia, RC; Reis, FR	1
Anderson, KI; Bleijerveld, OB; Corradini, E; Heck, AJ; Kolch, W; Müller, PJ; Preisinger, C; Scholten, A; Schwarz, JP	1
Glodkowska-Mrowka, E; Hoser, G; Kielak, M; Seferynska, I; Stoklosa, T; Wlodarski, P	1
Baccarani, M; Capdeville, R; Deininger, MW; Druker, BJ; Fernandes-Reese, S; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Hochhaus, A; Hoelzer, D; O'Brien, SG; Ottmann, OG; Reiffers, J; Sawyers, CL; Schiffer, CA; Silver, RT; Tura, S	1
Baiocchi, OC; Bordin, JO; Chauffaille, ML; Hungria, VT; Pelloso, LA; Yamamoto, M	1
Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J	1
Al-Ali, HK; Deininger, MW; Günther, C; Köhler, T; Krahl, R; Lange, T; Leiblein, S; Musiol, S; Niederwieser, D; van Hoomissen, I	1
Bhalla, K; Fuino, L; Nimmanapalli, R; Richon, V; Stobaugh, C	1
Hirose, Y; Ito, M; Iwai, M; Kiyoi, H; Naoe, T; Yokozawa, T	1
Arlinghaus, R; Donato, NJ; Gallick, G; Lin, H; Stapley, J; Talpaz, M; Wu, JY	1
Druker, BJ	1
Campbell, LJ; Januszewicz, EH; Patsouris, C; Rayeroux, KC; Somana, K; Szer, J	1
Goldman, JM; Marin, D	1
Alberti, D; Bungaro, S; Corneo, G; D'Incalci, M; Frapolli, R; Gambacorti-Passerini, C; Pioltelli, P; Pogliani, E; Rossi, F; Russo, D; Tornaghi, L; Verga, M; Zucchetti, M	1
Liu, NS; O'Brien, S	1
Chuah, CT; Goh, YT; Hwang, WY; Koh, LP; Linn, YC; Ng, HJ; Tan, CH; Tan, PH	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Fujisawa, S; Kobayashi, M; Yano, K	1
Hehlmann, R; Larson, R; Schiffer, CA	1
Ebnöther, M; Gratwohl, A; Heim, D; Linn, M; Meyer-Monard, S; Tichelli, A; Tsakiris, D	1
Bornhäuser, M; Griesinger, F; Gschaidmeier, H; Hochhaus, A; Hoelzer, D; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Thiede, C; Wassmann, B	1
Ikeda, Y; Mori, T; Okamoto, S; Yamazaki, R	1
Ahlgren, T; Barbouti, A; Fioretos, T; Höglund, M; Johansson, B; Lassen, C; Mitelman, F; Turesson, I	1
Bossone, G; Della Longa, G; Di Cocco, B; Salesi, N	1
Bányai, A; Barta, A; Dolgos, J; Gopcsa, L; Halm, G; Pálóczi, K	1
Asai, O; Dobashi, N; Kobayashi, M; Okawa, Y; Saito, T; Sugiyama, K; Takahara, S; Takei, Y; Uno, S; Usui, N; Yano, S	1
Fukuhara, T; Maekawa, I; Miyake, T; Onozawa, M; Takahata, M; Yamamoto, Y	1
Gordois, A; Scuffham, P; Ward, S; Warren, E	1
Czekalska, S; Czopek, J; Hanfstein, B; Hochhaus, A; Jakóbczyk, M; Müller, MC; Rudzki, Z; Sacha, T; Salamanchuk, Z; Skotnicki, AB; Wolska-Smoleń, T	1
Ikeda, Y; Miyazaki, K; Mori, T; Naito, K; Okamoto, S; Tsukada, Y	1
Brezinschek, R; Linkesch, W; Neumeister, P; Sill, H; Staber, PB	1
Atadja, P; Bali, P; Bhalla, K; Fuino, L; Gasparetto, M; Glozak, M; Jove, R; Moscinski, L; Nimmanapalli, R; Smith, C; Tao, J; Wu, J	1
Bader, P; Greil, J; Hochhaus, A; Koch, M; Kreyenberg, H; Lang, P; Niethammer, D; Scheel-Walter, H; Schumm, M	1
Chida, S; Endo, M; Hosokawa, T; Nakatuji, Y; Sugawara, W	1
Bastie, JN; Berthaud, P; Calvo, F; Chomienne, C; Degos, L; Larghero, J; Leguay, T; Madelaine-Chambrin, I; Mahon, FX; Marolleau, JP; Mourah, S; Raffoux, E; Rousselot, P; Taksin, AL	1
Carrasco, M; Conde, E; de Miguel, M; Díaz-Mediavilla, J; Martínez, JA; Sanz, MA; Sierra, J; Sureda, A	1
Deininger, M; Druker, BJ; La Rosée, P; Shen, L; Stoffregen, EP	1
Bornhauser, M; Ehninger, G; Freiberg-Richter, J; Jenke, A; Mohr, B; Radke, J; Schleyer, E; Schuler, US	1
Beck, J; Breitenbuecher, F; Duyster, J; Fischer, T; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A; Peschel, C; Theobald, M; Weinkauf, B	1
Hino, N; Myojo, T	1
Apperley, JF; Avery, S; Brito Babapulle, F; Goldman, JM; Kaeda, J; Marin, D; Nadal, E; Olavarria, E; Vulliamy, T	1
Komatsu, N; Kondo, T; Mitsugi, K; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Nakano, S; Ohmine, K; Ozawa, K; Tarumoto, T	1
Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G	1
Alimena, G; Breccia, M; Mancini, F; Mecarocci, S; Nanni, M; Russo, E	1
Bujassoum, S; Lipton, JH; Rifkind, J	1
Faber, E; Jarosová, M; Klamová, H; Michalová, K; Moravcová, J; Rabasová, J; Voglová, J; Zmeková, V	1
Chiyonobu, T; Imamura, T; Imashuku, S; Ishida, H; Morimoto, A; Ogami, A; Sugimoto, T; Takanashi, M; Yoshihara, T	1
Curtin, PT; Druker, BJ; Ford, JM; Leis, JF; Maziarz, RT; Peng, B; Schubach, S; Stepan, DE	1
Higashi, T; Iwashige, A; Kato, C; Machida, S; Mizobe, T; Morimoto, H; Ogawa, R; Tanaka, Y; Toda, Y; Tsukada, J	1
Hwang, JY; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JJ; Lee, S	1
Sato, Y; Tanizawa, Y; Yujiri, T	1
Clarke, MF	1
Ailles, LE; Dylla, SJ; Gotlib, J; Jamieson, CH; Jones, C; Keating, A; Li, K; Manz, MG; Muijtjens, M; Sawyers, CL; Weissman, IL; Zehnder, JL	1
Nguyen, PL; Wahner, AE; Xu, Y	1
Al-Beirouti, B; Keating, A; Lipton, JH; McCrae, J; Messner, HA; Rifkind, J; Song, KW; Yee, K	1
Curtin, PT; Druker, BJ; Leis, JF; Maziarz, RT; Primack, SL; Schubach, SE	1
Han, H; Han, JY; Kim, HJ; Kim, JS; Kim, SH; Kwon, HC; Lee, YH; Roh, MS; Seo, SY	1
Katayama, N; Masuya, M; Nakase, K; Nishii, K; Nomura, K; Ohishi, K; Sakakura, M; Shiku, H	1
Berger, U; Hehlmann, R; Hochhaus, A	1
Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Sondarva, G	1
Alimena, G; Breccia, M; Cimino, G; De Propris, MS; Diverio, D; Mancini, M; Mandelli, F; Nanni, M; Pane, F	1
Asaka, M; Dazai, M; Hashino, S; Imamura, M; Izumiyama, K; Kobayashi, S; Kondo, T; Morita, R; Onozawa, M; Ota, S; Sogabe, S	1
Cai, CC; Hong, WD; Li, J; Li, QH; Li, XH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D	1
Cohen, MH; Johnson, JR; Pazdur, R	1
Czepulkowski, B; Jan-Mohamed, R; Kaczmarski, R; Pavlu, J	1
Berger, U; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Riehm, B; Schoch, C; Schwindel, U	1
Berthebaud, M; Buet, D; Foudi, A; Geay, JF; Jarrier, P; Louache, F; Turhan, AG; Vainchenker, W; Zhang, Y	1
Abruzzese, E; Alberti, D; Amabile, M; Baccarani, M; Bassi, S; Castagnetti, F; Cilloni, D; de Vivo, A; Fava, M; Giannini, B; Izzo, B; Luatti, S; Martinelli, G; Pane, F; Poerio, A; Rosti, G; Saglio, G; Soverini, S; Testoni, N; Trabacchi, E	1
Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K	1
Hirase, C; Kanamaru, A; Maeda, Y; Matsuda, M; Miyatake, J; Morita, Y; Shimada, T; Tanaka, M; Tatsumi, Y	1
Raghunadharao, D; Rajappa, S; Rao, IS; Surath, A; Uppin, SG	1
Aleem, A; Siddiqui, N	1
Agirre, X; Barrios, M; Castillejo, JA; Cervantes, F; Colomer, D; Garate, L; Heiniger, A; Jimenez-Velasco, A; Navarro, G; Prosper, F; Roman-Gomez, J; Sanchez, J; Torres, A	1
Abruzzo, L; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Rios, MB; Verstovsek, S	1
Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Igarashi, T; Lundqvist, A; Rezvani, K; Savani, BN; Srinivasan, R; Takahashi, Y	1
Barnes, DJ; Goldman, JM; Melo, JV; Palaiologou, D; Panousopoulou, E; Pattacini, L; Schultheis, B; Wong, A; Yong, AS	1
Blaser, BW; Bloomfield, CD; Bruner-Klisovic, R; Caligiuri, MA; Chang, JS; Galietta, A; Liu, S; Mao, H; Marcucci, G; Neviani, P; Notari, M; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Uttam, A; Valtieri, M	1
Hyodo, H; Ito, T; Katayama, Y; Kimura, A; Miyoshi, N; Niimi, H; Tanaka, H	1
Ilaria, RL	1
Advani, SH; Borker, A	1
Allan, EK; Copland, M; Eaves, A; Eaves, C; Holyoake, TL; Jiang, X; Jørgensen, HG	1
Choufi, B; Dombret, H; Dupriez, B; Huguet, F; Legros, L; Maury, S; Ojeda-Uribe, M; Pigneux, A; Raffoux, E; Rea, D; Recher, C; Reman, O; Rousselot, P; Royer, B; Stéphane, D; Thomas, X; Turlure, P; Vigier, M	1
Abruzzo, LV; Han, X; Jones, D; Lin, P; Medeiros, LJ	1
Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M	1
Christen, S; Friess, D; Gratwohl, A; Heim, D; Meyer-Monard, S; Passweg, JR; Stüssi, G; Tichelli, A	1
Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Jones, D; Jones, R; Kantarjian, HM	1
Bertin, D; Crescenzio, N; Doria, A; Ricotti, E; Saglio, G; Timeus, F; Tovo, PA	1
Calabretta, B; Cattelani, S; Donato, NJ; Ferrari-Amorotti, G; Guerzoni, C; Iotti, G; Keeshan, K; Zattoni, M	1
Calbecka, M; Hellmann, A; Prejzner, W; Wyrowinska, E; Zaucha, JM	1
O'Brien, SG; Reilly, JT; Simpson, E	1
Asaka, M; Hashino, S; Imamura, M; Kondo, K; Matsuno, K; Mori, A; Musashi, M; Onozawa, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N	1
Alimena, G; Biondo, F; Breccia, M; Carmosino, I; Diverio, D; Latagliata, R; Mancini, M; Mandelli, F; Nanni, M; Russo, E	1
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B	1
Ahn, JS; Jung, CW; Kang, WK; Kim, HJ; Kim, K; Kim, WS; Ko, YH; Park, K	1
Chen, CK; Ikeda, Y; Mori, T; Okamoto, S; Saito, H; Sakamoto, M; Shibata, R; Tada, S; Yamazaki, R	1
Neviani, P; Perrotti, D	1
Estrov, Z; Kurzrock, R; Li, L; Talpaz, M	1
Andreeff, M; Carter, BZ; Dean, NM; Koller, E; Konopleva, M; Mak, DH; Schober, WD; Shi, Y; Wang, RY	1
Kumar, R; Pati, HP; Pillai, LS; Saxena, R; Srinivas, U	1
Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R	1
Azhipa, O; Friedman, TM; Goldberg, SL; Hsu, JW; Korngold, R; Pecora, AL; Preti, RA; Rowley, SD; Tkachuk, Y; Zilberberg, J	1
Beránek, M; Chrobák, L; Maisnar, V; Voglová, J	1
Büyükasik, Y; Cetiner, D; Goker, H; Haznedaroglu, IC; Koca, E; Ozcebe, O; Sayinalp, N; Sevimli, F	1
Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S	1
Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N	1
Bartholomeusz, GA; Donato, NJ; Estrov, Z; Kapuria, V; Kong, LY; Priebe, W; Talpaz, M; Wang, S; Wu, J	1
Michor, F	1
Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S	1
Bocchia, M; Calabrese, S; Crupi, R; Gozzetti, A; Lauria, F; Pirrotta, MT; Raspadori, D	1
Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I	1
Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W	1
Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J	1
Cao, G; Fang, B; Han, Z; Li, D; Lin, Q; Liu, X; Nie, N; Shi, Y; Song, Y; Sun, J; Tian, G; Wei, X; Yang, R; Zhao, RC; Zhu, X	1
Appio, L; Campiotti, L; Codari, R; Maria Grandi, A; Solbiati, F; Ultori, C; Venco, A	1
Duyster, J; Haferlach, C; Hochhaus, A; Menzel, H; Peschel, C; von Bubnoff, N	1
Wodarz, D	1
Broxmeyer, HE; Gotoh, A; Nakajima, A; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Sashida, G; Tauchi, T	1
Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM	1
Al Bahar, S; Pandita, R; Prakash, A; Ramamoorthy, SK; Ramaswamy, NV	1
Antolino, A; Berretta, S; Di Raimondo, F; Giustolisi, R; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P	1
Abakumov, EM; Abdulkadyrov, KM; Afanas'ev, BV; Chelysheva, EIu; Chernova, OA; Domracheva, EV; Druzhkova, GA; Goriacheva, SR; Ivanova, VL; Khoroshko, ND; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Kruglov, SS; Krylova, IV; Kuznetsov, SV; Liamkina, AS; Lomaia, EG; Loria, SS; Machiulaĭtene, ER; Martynkevich, IS; Nemchenko, IS; Ogorodnikova, IuS; Pospelova, TI; Shneĭder, TV; Sokolova, MA; Turkina, AG; Udal'eva, VIu; Vakhrusheva, MV; Vinogradova, OIu; Zakharova, AV; Zakharova, ES; Zaritskiĭ, AIu; Zhuravlev, VS	1
Chen, SS; Huang, XJ; Jiang, B; Jiang, Q; Qiu, JY; Zhang, Y	1
Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH	1
Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R	1
Amin, HM; Arlinghaus, RB; Ban, K; Bar-Eli, M; Chandra, J; Gao, Y; Howard, A; Leng, X; Lin, Q; Miller, C; Munsell, M	1
Busuttil, DP	1
Asada, N; Asakura, H; Koseki, M; Matsue, K; Takeuchi, M; Uryu, H	1
Corm, S; Deluche, L; Geffroy, S; Joha, S; Laï, JL; Nicolini, FE; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Tigaud, I	1
DeCoteau, JF; Geyer, CR; Lakshmikuttyamma, A; Pastural, E; Sawada, K; Sheridan, DP; Takahashi, N	1
Fu, Z; Jin, Z; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D	1
Al Bahar, S; Ramesh, P; Zámecníkova, A	1
Liu, XL; Zhang, S; Zhu, HQ	1
Bagg, A; Goldstein, SC; Kim, AS; Luger, S; Van Deerlin, VM	1
Chen, YZ; Huang, XW; Lin, Q; Wen, CX; Wu, LX; Xu, JH; Zhang, KZ	1
Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Liu, YR; Lu, DP; Lu, Y; Qin, YQ; Qiu, JY; Zhang, Y	1
Barlow, A; Doig, A; Drummond, MW; Robertson, M; Stewart, W	1
Druker, BJ; Kolibaba, KS; Ohno-Jones, S; Thiesing, JT	1
Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Reese, SF; Resta, DJ; Sawyers, CL; Talpaz, M	1
Barni, R; Corneo, GM; Gambacorti-Passerini, C; Marchesi, E; Pioltelli, P; Pogliani, E; Rossi, F; Verga, M	1
Nakajima, A; Ohyashiki, K; Tauchi, T	1
Ellwood, K; Gorre, ME; Hsu, N; Mohammed, M; Paquette, R; Rao, PN; Sawyers, CL	1
McCormick, F	1
Banerji, L; Deininger, MW; Goldman, JM; Köhler, T; Lam, EW; Mahon, FX; Melo, JV; Parada, Y; Peters, G; Vieira, SA	1
Calabretta, B; Caligiuri, MA; Campbell, K; Cesi, V; Condorelli, F; Gambacorti-Passerini, C; Guerzoni, C; Iervolino, A; Perrotti, D; Santilli, G; Trotta, R	1
Jinnai, I	1
Cornelissen, JJ; Löwenberg, B; Ossenkoppele, GJ; Shamelian, SO; Somers, JA	1
Ben-Am, M; Capdeville, R; Chapuis, B; Coutre, S; Deininger, MW; Druker, BJ; Feldman, E; Fischer, T; Gambacorti-Passerini, CB; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Larson, RA; Mandelli, F; Miller, CB; Morra, E; O'Brien, SG; Ottmann, OG; Paquette, RL; Peschel, C; Reiffers, JJ; Russell, NH; Saven, A; Sawyers, CL; Schiffer, CA; Shea, TC; Stone, RM; Talpaz, M; Tura, S	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA	1
Duba, HC; Gastl, G; Grünewald, K; Gunsilius, E; Hayes, M; Petzer, AL; Poewe, W; Schneller, F; Stockhammer, G	1
Anastasiadou, E; Borrow, J; Dash, AB; Druker, B; Gilliland, DG; Housman, D; Kutok, JL; Li, S; Lindahl, K; Tomasson, MH; Van Etten, RA; Williams, IR	1
Mayor, S	1

Reviews

23 review(s) available for imatinib mesylate and Blast Crisis

Article	Year
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. British journal of haematology, 2022, Volume: 199, Issue:5 Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors	2022
Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature. Journal of medical case reports, 2018, Sep-10, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Agents; Arthritis; Blast Crisis; Humans; Hypercalcemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	2018
Targeted drugs in chronic myeloid leukemia. Current medicinal chemistry, 2008, Volume: 15, Issue:29 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles	2008
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer investigation, 2009, Volume: 27, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine	2009
Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature. Leukemia research, 2009, Volume: 33, Issue:11 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2009
[Molecular pathogenesis of chronic myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Gene Silencing; Gene Targeting; Genes, Tumor Suppressor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction	2009
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Current hematologic malignancy reports, 2006, Volume: 1, Issue:3 Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles	2006
Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clinical neurology and neurosurgery, 2010, Volume: 112, Issue:7 Topics: Benzamides; Blast Crisis; Blood Cell Count; Diagnosis, Differential; Flow Cytometry; Humans; Imatinib Mesylate; In Situ Hybridization; Intracranial Hemorrhages; Leukemia, Biphenotypic, Acute; Leukocyte Count; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed	2010
Current treatment concepts of CML. Current cancer drug targets, 2011, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2011
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. The Journal of international medical research, 2011, Volume: 39, Issue:2 Topics: Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Publication Bias; Pyrimidines; Thiazoles; Treatment Outcome	2011
[Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:7 Topics: Adult; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2011
The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. Progress in molecular biology and translational science, 2012, Volume: 106 Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Autophagy; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Signal Transduction; src-Family Kinases	2012
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:22 Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles	2012
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome	2002
Management decisions in chronic myeloid leukemia. Seminars in hematology, 2003, Volume: 40, Issue:1 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Decision Making; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2003
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia, 2003, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biomarkers; Biomarkers, Tumor; Blast Crisis; Bone Marrow Examination; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Life Tables; Neoplasm Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis	2003
[A new drug in the therapy of chronic myeloid leukemia: ST1571]. Minerva medica, 2003, Volume: 94, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2003
Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate. Current hematology reports, 2003, Volume: 2, Issue:1 Topics: Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2003
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. European journal of haematology, 2004, Volume: 72, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction	2004
[Therapy of chronic myelogenous leukemia in 2004]. Deutsche medizinische Wochenschrift (1946), 2004, Oct-01, Volume: 129, Issue:40 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction	2004
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. British journal of cancer, 2006, Oct-09, Volume: 95, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Phosphoprotein Phosphatases; Piperazines; Protein Phosphatase 2; Proto-Oncogene Proteins c-bcr; Pyrimidines; Signal Transduction	2006
[Research advance on molecular genetics of CML blast crisis]. Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:1 Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic	2008
[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:1 Topics: Animals; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002

Trials

39 trial(s) available for imatinib mesylate and Blast Crisis

Article	Year
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial. International journal of hematology, 2022, Volume: 115, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Asian People; Blast Crisis; Disease Progression; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Young Adult	2022
Leukemia & lymphoma, 2022, Volume: 63, Issue:4 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome	2022
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of hematology, 2017, Volume: 96, Issue:9 Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Blast Crisis; Disease-Free Survival; Eosinophilia; Female; Follow-Up Studies; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Sex Factors; Survival Rate	2017
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2013, May-02, Volume: 121, Issue:18 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines	2013
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Current medical research and opinion, 2013, Volume: 29, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Polymerase Chain Reaction; Pyrimidines; Retrospective Studies; Survival Rate	2013
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Experimental hematology, 2014, Volume: 42, Issue:5 Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Blast Crisis; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; mRNA Cleavage and Polyadenylation Factors; Mutation, Missense; Neoplasms, Experimental; Oncogene Proteins, Fusion; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factor HES-1	2014
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c- Haematologica, 2015, Volume: 100, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Administration Schedule; Febrile Neutropenia; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mucositis; Mutation; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazoles	2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Blast Crisis; Diarrhea; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nitriles; Piperazines; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Survival Analysis; Treatment Outcome	2015
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leukemia & lymphoma, 2017, Volume: 58, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Retreatment; Treatment Outcome; Young Adult	2017
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia research, 2008, Volume: 32, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors	2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 2008, Volume: 22, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult	2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica, 2008, Volume: 93, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult	2008
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase Blood, 2009, May-21, Volume: 113, Issue:21 Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult	2009
Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clinical therapeutics, 2009, Volume: 31, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Benzamides; Blast Crisis; China; Chromatography, Liquid; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Tandem Mass Spectrometry; White People; Young Adult	2009
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Annals of hematology, 2010, Volume: 89, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Survival Rate	2010
Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Annals of hematology, 2010, Volume: 89, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Treatment Outcome; Young Adult	2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult	2010
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer, 2010, Aug-15, Volume: 116, Issue:16 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia research, 2011, Volume: 35, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult	2011
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leukemia & lymphoma, 2012, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult	2012
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Salvage Therapy; Survival Analysis	2002
High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood, 2003, Mar-15, Volume: 101, Issue:6 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Blast Crisis; Chemokines, CC; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Count; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Remission Induction; RNA, Messenger; Stem Cell Transplantation; Transplantation, Homologous; Tumor Cells, Cultured	2003
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2 Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Blast Crisis; Cell Division; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Orosomucoid; Piperazines; Protein Binding; Pyrimidines; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured	2003
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica, 2003, Volume: 88, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome	2003
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 2004, May-15, Volume: 103, Issue:10 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Count; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myeloid; Male; Middle Aged; Phosphorylation; Pilot Projects; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Treatment Outcome	2004
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & lymphoma, 2004, Volume: 45, Issue:4 Topics: Adult; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Tissue Distribution; Treatment Outcome	2004
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dose-Response Relationship, Drug; Drug Approval; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration	2005
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 2005, Apr-15, Volume: 103, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Chi-Square Distribution; Chromatography, High Pressure Liquid; Cytogenetic Analysis; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Point Mutation; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric; Survival Analysis	2005
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, Jan-15, Volume: 109, Issue:2 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Benzamides; Blast Crisis; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Treatment Outcome	2007
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, Apr-15, Volume: 109, Issue:8 Topics: Administration, Oral; Adult; Aged; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; src-Family Kinases; Thiazoles	2007
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer, 2007, Mar-01, Volume: 109, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Blast Crisis; Decitabine; DNA Methylation; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Survival Analysis; Treatment Outcome	2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 2007, Apr-15, Volume: 109, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2007
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib. Leukemia research, 2007, Volume: 31, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tetradecanoylphorbol Acetate; Treatment Outcome	2007
[Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Female; Follow-Up Studies; Hematopoiesis; Humans; Imatinib Mesylate; Incidence; Leukemia, Myeloid, Chronic-Phase; Leukocyte Count; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Russia; Survival Rate; Time Factors	2007
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine, 2001, Apr-05, Volume: 344, Issue:14 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction	2001
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytogenetic Analysis; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome	2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome	2002

Other Studies

220 other study(ies) available for imatinib mesylate and Blast Crisis

Article	Year
Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance. Journal of pediatric hematology/oncology, 2022, Apr-01, Volume: 44, Issue:3 Topics: Blast Crisis; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction	2022
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. Haematologica, 2022, 12-01, Volume: 107, Issue:12 Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction	2022
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood, 2023, 06-01, Volume: 141, Issue:22 Topics: Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors	2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood cancer journal, 2023, 09-11, Volume: 13, Issue:1 Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Splenomegaly	2023
microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients. Asian Pacific journal of cancer prevention : APJCP, 2019, 08-01, Volume: 20, Issue:8 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blast Crisis; Case-Control Studies; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Prognosis; Survival Rate	2019
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 119 Topics: 3' Untranslated Regions; Aminopyridines; Base Sequence; Benzamides; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oncogenes; Protein Biosynthesis	2019
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study. European journal of cancer (Oxford, England : 1990), 2020, Volume: 137 Topics: Adolescent; Blast Crisis; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male	2020
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia. The Pan African medical journal, 2020, Volume: 36 Topics: Adolescent; Algeria; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Central Nervous System; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Recurrence	2020
A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia. Nature communications, 2020, 11-26, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Blast Crisis; Chemoradiotherapy; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Gene Knockout Techniques; Genes, Reporter; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Integrin beta Chains; Leukemia, Myeloid, Acute; Mice, Transgenic; Neoplastic Stem Cells; RNA-Binding Proteins; RNA-Seq; Signal Transduction; Syndecan-1	2020
CML in blast crisis: more common than we think? Blood, 2017, 05-18, Volume: 129, Issue:20 Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2017
The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML. Blood, 2017, 09-07, Volume: 130, Issue:10 Topics: Adult; Antineoplastic Agents; Blast Crisis; Bone Marrow; Chromosomes, Human, Pair 8; Genes, myc; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Protein Kinase Inhibitors	2017
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved. International journal of hematology, 2018, Volume: 107, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Substitution; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2018
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system. British journal of haematology, 2018, Volume: 183, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Dasatinib; Drug Administration Schedule; Drug Substitution; Fatal Outcome; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyridazines; Pyrimidines; Recurrence	2018
The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of medical economics, 2018, Volume: 21, Issue:7 Topics: Age Factors; Blast Crisis; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Socioeconomic Factors	2018
Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). Experimental hematology, 2018, Volume: 64 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Cohort Studies; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Random Allocation; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Transcriptome	2018
Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Experimental hematology, 2018, Volume: 64 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cause of Death; Child; Disease-Free Survival; Female; Follow-Up Studies; France; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult	2018
An atypical isolated CNS blast crisis in chronic myeloid leukaemia. British journal of hospital medicine (London, England : 2005), 2018, Aug-02, Volume: 79, Issue:8 Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome	2018
[Chronic Myelogenous Leukemia]. Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:18 Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Neoplastic; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines	2018
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling. Biochemical and biophysical research communications, 2018, 11-02, Volume: 505, Issue:3 Topics: Anisomycin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Wnt Signaling Pathway	2018
Acquisition of Inv(16)(p13q22) in a blast crisis of chronic myeloid leukemia: case report. Medicina clinica, 2019, 05-17, Volume: 152, Issue:10 Topics: Abnormal Karyotype; Adult; Antineoplastic Agents; Blast Crisis; Chromosome Inversion; Chromosomes, Human, Pair 16; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Translocation, Genetic; Trisomy	2019
Haematologica, 2019, Volume: 104, Issue:9 Topics: Blast Crisis; Cell Differentiation; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Sequence Analysis, DNA; Ubiquitin-Conjugating Enzymes	2019
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. International journal of oncology, 2019, Volume: 54, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HLA-A24 Antigen; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Phosphatase 2; Quinolones; Thiophenes; Young Adult	2019
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Medicina clinica, 2013, Aug-04, Volume: 141, Issue:3 Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles	2013
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia, 2013, Volume: 27, Issue:11 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Eosinophilia; Follow-Up Studies; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lymphoma, T-Cell; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Myeloid; Survival Rate	2013
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. The Journal of experimental medicine, 2013, Oct-21, Volume: 210, Issue:11 Topics: Animals; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunophenotyping; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Neoplastic Stem Cells; Piperazines; Pyrimidines; Side-Population Cells; Wnt Signaling Pathway	2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 2014, Feb-01, Volume: 120, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine	2014
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22 Topics: Adolescent; Adult; Benzamides; Blast Crisis; Case-Control Studies; Chromosome Breakpoints; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult	2014
Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience. Leukemia & lymphoma, 2015, Volume: 56, Issue:8 Topics: Antineoplastic Agents; Blast Crisis; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genetic Variation; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome	2015
[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1 Topics: Benzamides; Blast Crisis; Cytogenetics; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome	2015
[Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome	2015
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PloS one, 2015, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Chromosome Breakage; Clonal Evolution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Proteolysis; Separase; Young Adult	2015
Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Bone Marrow; Female; Granulocyte Precursor Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors	2015
Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country. Clinical therapeutics, 2015, Nov-01, Volume: 37, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Blast Crisis; Cohort Studies; Cross-Sectional Studies; Developing Countries; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult	2015
Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations. Science China. Life sciences, 2015, Volume: 58, Issue:12 Topics: Blast Crisis; Clone Cells; Complementarity Determining Regions; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Proto-Oncogene Proteins c-abl; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction	2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget, 2015, Oct-13, Volume: 6, Issue:31 Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Blast Crisis; Cell Proliferation; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2015
[The expression and role of the transcription factor C/EBPα in chronic myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:11 Topics: Blast Crisis; Bone Marrow; Case-Control Studies; CCAAT-Enhancer-Binding Protein-alpha; Cell Cycle; Cell Proliferation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transfection	2015
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood, 2016, 04-28, Volume: 127, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; Blast Crisis; Cell Division; Cell Line, Tumor; Cytostatic Agents; Gene Expression Regulation, Leukemic; Genes, abl; Genes, Tumor Suppressor; Genomic Instability; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Experimental; Leukemia, Myeloid, Chronic-Phase; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Oxidative Stress; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Tumor Suppressor Proteins	2016
[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:1 Topics: Blast Crisis; Cytogenetics; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Pyrimidines	2016
Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells. PloS one, 2016, Volume: 11, Issue:3 Topics: Apoptosis; Autophagy; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor	2016
Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Current medical research and opinion, 2016, Volume: 32, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quality of Life; Quinolines	2016
High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia. International journal of hematology, 2016, Volume: 104, Issue:3 Topics: Apoptosis; Blast Crisis; Bone Marrow; Cells, Cultured; Coculture Techniques; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Signal Transduction	2016
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib. Pediatric blood & cancer, 2016, Volume: 63, Issue:12 Topics: Antineoplastic Agents; Blast Crisis; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	2016
[Comparative Analysis of Efficacy and Drug Resistance of Imatinib in Patients with Chronic Myeloid Leukemia at Chronic and Advanced Phases]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Blast Crisis; Cytogenetics; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction; Survival Rate	2016
A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations. Methods in molecular biology (Clifton, N.J.), 2016, Volume: 1465 Topics: Apoptosis; Blast Crisis; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Pyrimidines	2016
Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis. Archives of pathology & laboratory medicine, 2008, Volume: 132, Issue:6 Topics: Aged; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Erythrocytes; Fatal Outcome; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2008
Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leukemia & lymphoma, 2008, Volume: 49, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Telomere; Transcription, Genetic; Tumor Cells, Cultured	2008
Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes, chromosomes & cancer, 2008, Volume: 47, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2008
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World journal of pediatrics : WJP, 2008, Volume: 4, Issue:2 Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2008
Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment. Annals of clinical and laboratory science, 2008,Summer, Volume: 38, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Treatment Outcome; Tretinoin	2008
In vitro anti-leukaemia activity of sphingosine kinase inhibitor. British journal of haematology, 2009, Volume: 144, Issue:3 Topics: Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors	2009
Presentation of childhood CML mimicking bone sarcoma. Pediatric blood & cancer, 2009, Volume: 52, Issue:7 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Neoplasms; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Osteosarcoma; Piperazines; Pyrimidines	2009
Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib. Bone marrow transplantation, 2009, Volume: 44, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome	2009
The CML stem cell: evolution of the progenitor. Cell cycle (Georgetown, Tex.), 2009, May-01, Volume: 8, Issue:9 Topics: Animals; Benzamides; Biological Evolution; Blast Crisis; Granulocyte-Macrophage Progenitor Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines	2009
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica, 2009, Volume: 94, Issue:5 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase II as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Piperazines; Pyrimidines; Treatment Outcome	2009
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Analysis of Variance; Benzamides; Blast Crisis; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Pharmacogenetics; Piperazines; Probability; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome	2009
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 2009, Sep-10, Volume: 114, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine	2009
Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? British journal of haematology, 2009, Volume: 146, Issue:4 Topics: Antigens; Aurora Kinases; Benzamides; Biomarkers; Blast Crisis; Blotting, Western; Case-Control Studies; Cell Cycle Proteins; Centrioles; Centrosome; Endopeptidases; Flow Cytometry; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoprecipitation; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myeloid, Chronic-Phase; Microtubule-Associated Proteins; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Separase; Statistics, Nonparametric; Survivin	2009
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American journal of hematology, 2009, Volume: 84, Issue:10 Topics: Antineoplastic Agents; Aphasia; Ataxia; Benzamides; Blast Crisis; Confusion; Cytarabine; Diagnosis, Differential; Hearing Loss; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2009
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Molecular cancer therapeutics, 2009, Volume: 8, Issue:9 Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Blast Crisis; Blotting, Western; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrenes; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2009
Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way. Cancer cell, 2009, Sep-08, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Cytidine Deaminase; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Piperazines; Pyrimidines	2009
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer cell, 2009, Sep-08, Volume: 16, Issue:3 Topics: Animals; B-Lymphocytes; Benzamides; Blast Crisis; Cell Line, Tumor; Cytidine Deaminase; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases, Renilla; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, SCID; Mice, Transgenic; Mutation; Piperazines; Pyrimidines; Xenograft Model Antitumor Assays	2009
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. Cytotherapy, 2010, Volume: 12, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome	2010
The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia. Acta haematologica, 2010, Volume: 123, Issue:1 Topics: Antigens, CD34; Base Sequence; Benzamides; Blast Crisis; DNA Primers; DNA-Binding Proteins; Gene Expression; Genes, abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Piperazines; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Stem Cell Transplantation; Transcription Factors	2010
Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. International journal of clinical oncology, 2009, Volume: 14, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosome Aberrations; Cytogenetic Analysis; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2009
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene, 2010, May-20, Volume: 29, Issue:20 Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Ribose; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays	2010
Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Child; Cord Blood Stem Cell Transplantation; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome	2010
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic	2010
Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Experimental hematology, 2010, Volume: 38, Issue:9 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Cattle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Transplantation; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; Transplantation, Heterologous	2010
Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells. Annals of hematology, 2011, Volume: 90, Issue:3 Topics: Adult; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Clone Cells; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Precursor Cells, B-Lymphoid; Pyrimidines	2011
[Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:8 Topics: Adolescent; Adult; Benzamides; beta Catenin; Blast Crisis; Case-Control Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Young Adult	2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood, 2010, Dec-23, Volume: 116, Issue:26 Topics: Benzamides; Blast Crisis; Dasatinib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Thiazoles; Transcription Factors	2010
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib. Acta haematologica, 2010, Volume: 124, Issue:3 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzamides; Blast Crisis; Clofarabine; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Homologous	2010
[A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia]. The Korean journal of laboratory medicine, 2010, Volume: 30, Issue:6 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosomes, Human, Pair 3; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic	2010
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutagenesis, Insertional; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines	2011
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. Leukemia research, 2011, Volume: 35, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction	2011
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leukemia research, 2011, Volume: 35, Issue:10 Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous	2011
Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cellular signalling, 2011, Volume: 23, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blast Crisis; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; STAT5 Transcription Factor; Telomerase; Transcription, Genetic; Transcriptional Activation	2011
Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematologic Tests; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome	2011
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. Journal of translational medicine, 2011, Apr-21, Volume: 9 Topics: Adolescent; Adult; Apoptosis; Benzamides; BH3 Interacting Domain Death Agonist Protein; Blast Crisis; Blood Cells; Cell Respiration; Cluster Analysis; Culture Media; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Models, Biological; Monocyclic Sesquiterpenes; Mutation; Piperazines; Pyrimidines; Sesquiterpenes; Solubility; Time Factors; Tumor Cells, Cultured; Young Adult	2011
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Leukemia research, 2011, Volume: 35, Issue:10 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2011
Chronic myelogenous leukemia in the chronic phase with lymph node swelling which represented extramedullary involvement composed of cells at different stages of maturation. Rinsho byori. The Japanese journal of clinical pathology, 2011, Volume: 59, Issue:4 Topics: Benzamides; Blast Crisis; Fatal Outcome; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymph Nodes; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2011
An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report. Annals of hematology, 2012, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Erythroid Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed	2012
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India. Clinical laboratory, 2011, Volume: 57, Issue:7-8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles	2011
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia. International journal of oncology, 2012, Volume: 40, Issue:2 Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult	2012
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia, 2012, Volume: 26, Issue:4 Topics: Antigens, CD34; Apoptosis; Benzamides; Biphenyl Compounds; Blast Crisis; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitrophenols; Phenanthrenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Messenger; Signal Transduction; Sulfonamides	2012
Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. International journal of hematology, 2011, Volume: 94, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia, 2012, Volume: 26, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Young Adult	2012
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Adult; Aged; Benzamides; Blast Crisis; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult	2012
Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematological oncology, 2012, Volume: 30, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kidney; Leukemia, Myeloid, Chronic-Phase; Liver; Male; Middle Aged; Patient Compliance; Piperazines; Prognosis; Pyrimidines; Tissue Distribution; Young Adult	2012
Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML. Acta haematologica, 2012, Volume: 127, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2012
[Rapamycin for myeloid blast crisis in refractory chronic myeloid leukemia with imatinib-resistance]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:8 Topics: Adult; Antibiotics, Antineoplastic; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Sirolimus	2011
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood, 2012, May-03, Volume: 119, Issue:18 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease Management; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Time Factors	2012
Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib. Leukemia research, 2012, Volume: 36, Issue:6 Topics: Abdomen; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Middle Aged; Piperazines; Pyrimidines; Tomography, Emission-Computed	2012
Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Benzamides; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines	2012
[Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; CpG Islands; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; Trans-Activators	2012
The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. PloS one, 2012, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Cycle Proteins; Cyclin B1; Drug Resistance, Neoplasm; Endopeptidases; Fusion Proteins, bcr-abl; Genomic Instability; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Phosphatase 2; Proteolysis; Pyrimidines; Securin; Separase; U937 Cells	2012
Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells. Leukemia research, 2012, Volume: 36, Issue:12 Topics: Annexin A5; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blast Crisis; Blotting, Western; Cell Nucleus; Cell Survival; Cytoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survivin	2012
Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Leukemia, 2013, Volume: 27, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Membrane; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Phosphotyrosine; Piperazines; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Tyrosine	2013
Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia. Experimental hematology, 2013, Volume: 41, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Blotting, Western; Cell Line; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2013
Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. European journal of haematology, 2002, Volume: 69, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Pyrimidines	2002
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer research, 2002, Oct-15, Volume: 62, Issue:20 Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators	2002
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 2003, Apr-15, Volume: 101, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle Proteins; Computer Systems; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Disease Progression; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vorinostat	2003
Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. International journal of hematology, 2002, Volume: 76, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Primary Myelofibrosis; Pyrimidines	2002
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 2003, Jan-15, Volume: 101, Issue:2 Topics: Benzamides; Blast Crisis; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Selection, Genetic; src-Family Kinases	2003
BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer genetics and cytogenetics, 2002, Volume: 139, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Banding; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2002
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. Leukemia & lymphoma, 2002, Volume: 43, Issue:12 Topics: Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2002
Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone marrow transplantation, 2003, Volume: 31, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Time Factors; Treatment Outcome	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
[A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:3 Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Transplantation; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction	2003
G-CSF for imatinib-induced neutropenia. Leukemia, 2003, Volume: 17, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines	2003
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone marrow transplantation, 2003, Volume: 31, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous	2003
Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis. British journal of haematology, 2003, Volume: 121, Issue:4 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Piperazines; Pyrimidines	2003
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. British journal of haematology, 2003, Volume: 122, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Enzyme Inhibitors; Fatal Outcome; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence	2003
Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. Pathology oncology research : POR, 2003, Volume: 9, Issue:2 Topics: Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Tissue Donors; Transplantation, Homologous; Treatment Outcome	2003
[Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:6 Topics: Adult; Benzamides; Blast Crisis; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pulse Therapy, Drug; Pyrimidines; Remission Induction; Treatment Outcome	2003
A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL. Annals of hematology, 2003, Volume: 82, Issue:9 Topics: Aged; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Translocation, Genetic	2003
Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Markov Chains; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Survival Rate	2003
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia research, 2003, Volume: 27, Issue:12 Topics: Adenosine Triphosphate; Adult; Amino Acid Sequence; Base Sequence; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Sequence Data; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines; Sequence Homology, Nucleic Acid	2003
Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:8 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Examination; Bone Marrow Transplantation; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Node Excision; Male; Neck; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2003
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. Haematologica, 2003, Volume: 88, Issue:8 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Transplantation, Homologous	2003
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer research, 2003, Aug-15, Volume: 63, Issue:16 Topics: Acetylation; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Piperazines; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Pyridones; Pyrimidines; Tumor Cells, Cultured	2003
Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male. Bone marrow transplantation, 2003, Volume: 32, Issue:5 Topics: Adolescent; Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2003
[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:9 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Child; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction	2003
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochemical pharmacology, 2003, Nov-15, Volume: 66, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orosomucoid; Piperazines; Pyrimidines; Tumor Cells, Cultured	2003
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). The hematology journal : the official journal of the European Haematology Association, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Division; Cell Survival; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured	2003
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Annals of hematology, 2004, Volume: 83, Issue:6 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2004
Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:2 Topics: Benzamides; Blast Crisis; Bone Marrow; Genes, abl; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2004
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Aged; Benzamides; Blast Crisis; Cell Transformation, Neoplastic; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction	2004
Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Experimental hematology, 2004, Volume: 32, Issue:4 Topics: Antineoplastic Agents; Ascorbic Acid; Benzamides; Blast Crisis; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Glutamate-Cysteine Ligase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-E2-Related Factor 2; Oxidative Stress; Piperazines; Protein Transport; Pyrimidines; Regulatory Sequences, Nucleic Acid; RNA, Neoplasm; Trans-Activators	2004
Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica, 2004, Volume: 89, Issue:4 Topics: Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy	2004
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leukemia & lymphoma, 2004, Volume: 45, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2004
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia research, 2004, Volume: 28, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2004
Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. Journal of pediatric hematology/oncology, 2004, Volume: 26, Issue:5 Topics: Adolescent; Benzamides; Blast Crisis; Cytogenetic Analysis; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Activation; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous	2004
Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. American journal of hematology, 2004, Volume: 76, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Chromosome Aberrations; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Remission Induction; RNA, Messenger	2004
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia, 2004, Volume: 18, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Failure	2004
Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation. International journal of hematology, 2004, Volume: 80, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Genes, abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous	2004
Chronic myelogenous leukemia--identifying the hydra's heads. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Antineoplastic Agents; Benzamides; beta Catenin; Blast Crisis; Cytoskeletal Proteins; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multipotent Stem Cells; Piperazines; Pyrimidines; Trans-Activators	2004
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; beta Catenin; Blast Crisis; Colony-Forming Units Assay; Cytoskeletal Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Granulocytes; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Enhancer-Binding Factor 1; Macrophages; Male; Microscopy, Confocal; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Trans-Activators; Transcription Factors	2004
Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Archives of pathology & laboratory medicine, 2004, Volume: 128, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Cytogenetic Analysis; Disease Progression; Fibrosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2004
Subdural hematomas during CML therapy with imatinib mesylate. Leukemia & lymphoma, 2004, Volume: 45, Issue:8 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Risk Factors; Thrombocytopenia; Treatment Outcome	2004
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. Haematologica, 2004, Volume: 89, Issue:9 Topics: Aged; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Dyspnea; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Lung; Male; Piperazines; Pyrimidines; Remission Induction; Tomography, X-Ray Computed	2004
Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1. Cancer genetics and cytogenetics, 2004, Oct-01, Volume: 154, Issue:1 Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Translocation, Genetic	2004
Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin. American journal of hematology, 2004, Volume: 77, Issue:2 Topics: Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymph Nodes; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Retroperitoneal Neoplasms	2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, Feb-15, Volume: 105, Issue:4 Topics: Acute Disease; Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Cell Line, Tumor; Drug Combinations; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Gene Deletion; Gene Expression Regulation; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Panobinostat; Piperazines; Point Mutation; Polyubiquitin; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rifabutin	2005
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. Leukemia, 2005, Volume: 19, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Catalytic Domain; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Treatment Outcome	2005
[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:10 Topics: Bacterial Infections; Benzamides; Blast Crisis; Drug Therapy, Combination; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction	2004
[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction; Survival Rate	2004
Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blindness; Central Nervous System; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 6; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Retina; Trisomy	2005
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer research, 2005, Apr-01, Volume: 65, Issue:7 Topics: Animals; Antigens, CD34; Benzamides; Blast Crisis; Cell Line; Chemokine CXCL12; Chemokines, CXC; Down-Regulation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; NIH 3T3 Cells; Piperazines; Pluripotent Stem Cells; Pyrimidines; Receptors, CXCR4; Signal Transduction; Transcription, Genetic	2005
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochemical pharmacology, 2005, Jun-01, Volume: 69, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones	2005
Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. International journal of hematology, 2005, Volume: 81, Issue:4 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System Neoplasms; Clone Cells; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2005
Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematological oncology, 2004, Volume: 22, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meninges; Methotrexate; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2004
Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. Leukemia & lymphoma, 2005, Volume: 46, Issue:7 Topics: Antineoplastic Agents; Ascites; Benzamides; Blast Crisis; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2005
Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene, 2005, Nov-03, Volume: 24, Issue:48 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; CpG Islands; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Long Interspersed Nucleotide Elements; Male; Middle Aged; Multivariate Analysis; Open Reading Frames; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrimidines; Regression Analysis; Retroelements; Transcription, Genetic; Treatment Outcome	2005
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood, 2006, Jan-15, Volume: 107, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous	2006
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:10 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer research, 2005, Oct-01, Volume: 65, Issue:19 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Stem Cells	2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer cell, 2005, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Transformed; Chromosomal Proteins, Non-Histone; Colforsin; DNA-Binding Proteins; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Chaperones; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplasm Transplantation; Phosphoprotein Phosphatases; Piperazines; Protein Phosphatase 2; Pyrimidines; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins	2005
Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase. International journal of hematology, 2005, Volume: 82, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Female; Humans; Hypercalcemia; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Parathyroid Hormone-Related Protein; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2005
Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology. American Society of Hematology. Education Program, 2005 Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2005
Testicular involvement in blast crisis of chronic myeloid leukemia. Indian pediatrics, 2005, Volume: 42, Issue:11 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Fatal Outcome; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Testicular Diseases	2005
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Culture Media, Serum-Free; Drug Combinations; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Granulocyte Colony-Stimulating Factor; RNA, Messenger; Tumor Cells, Cultured	2006
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 2006, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vincristine	2006
Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis. American journal of clinical pathology, 2006, Volume: 125, Issue:1 Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines	2006
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. European journal of haematology, 2006, Volume: 76, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2006
Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia. Leukemia, 2006, Volume: 20, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Dose-Response Relationship, Drug; Fatal Outcome; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Risk Factors; Transplantation, Autologous; Treatment Outcome	2006
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Adult; Benzamides; Blast Crisis; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Graft Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2006
The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. Haematologica, 2006, Volume: 91, Issue:5 Topics: Adolescent; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Imatinib Mesylate; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrimidines; Saquinavir	2006
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Animals; Benzamides; Blast Crisis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2006
Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Clinical and laboratory haematology, 2006, Volume: 28, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Recombinant Proteins	2006
Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. Clinical and laboratory haematology, 2006, Volume: 28, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Brain Neoplasms; Fatal Outcome; Female; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms	2006
Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients. Acta haematologica, 2006, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Proliferation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Leukemic; Genes, abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Pyrimidines	2006
Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer, 2006, Sep-01, Volume: 107, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2006
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine	2006
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cerebellum; Drug Administration Schedule; Fatal Outcome; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2006
Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leukemia & lymphoma, 2006, Volume: 47, Issue:7 Topics: Antineoplastic Agents; Benzamides; Biopsy; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Middle Aged; Piperazines; Pyrimidines	2006
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leukemia & lymphoma, 2006, Volume: 47, Issue:8 Topics: Benzamides; Blast Crisis; Cell Line; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; Transfection	2006
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell cycle (Georgetown, Tex.), 2006, Volume: 5, Issue:19 Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kinesins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Piperazines; Pyrimidines; Transplantation, Heterologous	2006
Bone marrow aplasia--a rare complication of imatinib therapy in CML patients. American journal of hematology, 2007, Volume: 82, Issue:4 Topics: Adolescent; Adult; Anemia, Aplastic; Benzamides; Blast Crisis; Bone Marrow Examination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pancytopenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2007
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, Nov-07, Volume: 103, Issue:45 Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles	2006
Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Adult; Animals; Antilymphocyte Serum; Benzamides; Blast Crisis; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Female; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocyte Depletion; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Rabbits; Remission Induction; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2006
[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]. Vnitrni lekarstvi, 2006, Volume: 52, Issue:9 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thrombocytosis	2006
Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia. American journal of hematology, 2007, Volume: 82, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survivors; Treatment Refusal; Vincristine	2007
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood, 2007, Apr-15, Volume: 109, Issue:8 Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Cyanoacrylates; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Tumor Stem Cell Assay	2007
Chronic myeloid leukemia blast crisis arises from progenitors. Stem cells (Dayton, Ohio), 2007, Volume: 25, Issue:5 Topics: Benzamides; Blast Crisis; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Immunological; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines	2007
Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta haematologica, 2007, Volume: 117, Issue:4 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Genes, abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2007
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. Journal of neuro-oncology, 2007, Volume: 84, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome	2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia & lymphoma, 2007, Volume: 48, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome	2007
Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis. Leukemia research, 2007, Volume: 31, Issue:12 Topics: Aged; Benzamides; Blast Crisis; Bone Marrow Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Necrosis; Piperazines; Pyrimidines	2007
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone marrow transplantation, 2007, Volume: 40, Issue:1 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2007
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Medical hypotheses, 2008, Volume: 70, Issue:1 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Disease Progression; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells	2008
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem cells and development, 2007, Volume: 16, Issue:3 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line; Cell Proliferation; Depsipeptides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Piperazines; Pyrimidines; Telomerase; Tumor Cells, Cultured	2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of clinical investigation, 2007, Volume: 117, Issue:9 Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured	2007
Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. Acta haematologica, 2007, Volume: 118, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Jaundice, Obstructive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Piperazines; Pyrimidines	2007
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leukemia research, 2008, Volume: 32, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles	2008
[The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]. Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines	2007
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2007
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles	2008
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Animals; Benzamides; Blast Crisis; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-fyn; Pyrimidines; Up-Regulation	2008
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival. International journal of laboratory hematology, 2008, Volume: 30, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Survivors; Thrombocytopenia	2008
Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. International journal of hematology, 2007, Volume: 86, Issue:5 Topics: Acute Disease; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antineoplastic Agents; Antithrombin III; Benzamides; Blast Crisis; Blood Transfusion; Bone Marrow Transplantation; Colon; Colonic Diseases; Disseminated Intravascular Coagulation; Fibrinolysin; Gastrointestinal Hemorrhage; Genes, abl; Heparin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peptide Hydrolases; Piperazines; Pyrimidines; Shock; Tranexamic Acid; Transplantation, Homologous	2007
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood, 2008, Apr-01, Volume: 111, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosomes, Human; Chronic Disease; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Piperazines; Point Mutation; Pyrimidines; Retrospective Studies; Survival Rate; Transcription Factors; Translocation, Genetic; Trisomy	2008
Bcr-Abl induces autocrine IGF-1 signaling. Oncogene, 2008, Jun-19, Volume: 27, Issue:27 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-hck; Pyrimidines; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor	2008
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. International journal of hematology, 2008, Volume: 87, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Transplantation, Homologous	2008
Trisomy 6 in a CML patient receiving imatinib mesylate therapy. Leukemia research, 2008, Volume: 32, Issue:9 Topics: Adult; Benzamides; Blast Crisis; Chromosomes, Human, Pair 6; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Trisomy	2008
Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? American journal of clinical pathology, 2008, Volume: 129, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Female; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Lymph Nodes; Male; Piperazines; Pyrimidines; Remission Induction; RNA, Neoplasm	2008
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia, 2008, Volume: 22, Issue:7 Topics: Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Caspase 3; Caspase 9; Cell Proliferation; Cytochromes c; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoprecipitation; K562 Cells; Lactams, Macrocyclic; Leukemia; Novobiocin; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines	2008
[The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2007, Volume: 28, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2007
Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission. British journal of haematology, 2008, Volume: 142, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Dasatinib; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes; Thiazoles	2008
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 2000, Nov-01, Volume: 96, Issue:9 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-3; Leukemia, Megakaryoblastic, Acute; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Stem Cell Factor; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. British journal of haematology, 2001, Volume: 112, Issue:4 Topics: Adult; Aged; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Tumor Cells, Cultured	2001
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia, 2001, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Oncogene Proteins v-abl; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Pyrimidines; Substrate Specificity; Tumor Cells, Cultured	2001
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.), 2001, Aug-03, Volume: 293, Issue:5531 Topics: Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Blast Crisis; Cell Line; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Philadelphia Chromosome; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-crk; Pyrimidines; Recurrence; Signal Transduction	2001
New-age drug meets resistance. Nature, 2001, Jul-19, Volume: 412, Issue:6844 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Approval; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; United States	2001
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer research, 2001, Nov-01, Volume: 61, Issue:21 Topics: Benzamides; Blast Crisis; Cyclin D2; Cyclins; Down-Regulation; Fusion Proteins, bcr-abl; G1 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Phosphatidylinositol 3-Kinases; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; S Phase; Signal Transduction; Transfection	2001
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nature genetics, 2002, Volume: 30, Issue:1 Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Carrier Proteins; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; DNA-Binding Proteins; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Neoplasm Proteins; Neoplastic Stem Cells; Oligodeoxyribonucleotides; Piperazines; Protein Biosynthesis; Protein Isoforms; Pyrimidines; Receptors, Granulocyte Colony-Stimulating Factor; RNA-Binding Proteins; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Transcription Factors; Transcription, Genetic; Transfection	2002
[STI571: a new dimension in the treatment of chronic myeloid leukemia]. Nederlands tijdschrift voor geneeskunde, 2002, Jan-19, Volume: 146, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Drug Approval; Enzyme Inhibitors; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; United States	2002
Low concentrations of STI571 in the cerebrospinal fluid: a case report. British journal of haematology, 2002, Volume: 117, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Enzyme Inhibitors; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America, 2002, May-28, Volume: 99, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Bone Marrow Transplantation; Cell Division; Cloning, Molecular; Disease Models, Animal; Disease Progression; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Proteins; Mice; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Piperazines; Proviruses; Pyrimidines; Tumor Cells, Cultured	2002
Doctors condemn NICE's guidance on leukaemia drug. BMJ (Clinical research ed.), 2002, Jun-08, Volume: 324, Issue:7350 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Government Agencies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; United Kingdom	2002